NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/05/2024
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Descrição da marca
The mark consists of the stylized wording "OXY". The "O" and "X" are in blue, and the "Y" is in blue and purple. Below this wording is the stylized wording "GENE". The "G" is in blue and purple, the "E" is in blue, purple, and orange, and the "N" and "E" are in orange. There is a stylized blue, purple, red, and orange incomplete, wavy circle to the left of the wording that extends towards the right. The color white represents background and is not claimed as a part of the mark.
Titulares
Representantes
Monte L. Falcoff/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Supply in the nature of custom manufacture of production units for biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; contract manufacturing for others of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; production in the nature of custom manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Classe 42
Study in the nature of conducting scientific feasibility studies and design of production factories and buildings; inspection of production factories and buildings for quality control and consultancy purposes; engineering; preparation of technical studies; quality control of production units in the pharmaceutical and biopharmaceutical field with a view to certification; research and development of new products for third parties; technological services regarding manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Histórico de despachos e eventos da marca no USPTO.
53 publicações encontradas
NEW REPRESENTATIVE AT IB RECEIVED
04/05/2024
FINAL DECISION TRANSACTION PROCESSED BY IB
23/05/2022
FINAL DISPOSITION NOTICE SENT TO IB
03/05/2022
FINAL DISPOSITION PROCESSED
03/05/2022
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
16/02/2022
REGISTERED-PRINCIPAL REGISTER
16/11/2021
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/08/2021
PUBLISHED FOR OPPOSITION
31/08/2021
NOTIFICATION PROCESSED BY IB
29/08/2021
ASSIGNED TO EXAMINER
23/08/2021
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/08/2021
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/08/2021
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/08/2021
EXPARTE APPEAL TERMINATED
25/07/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
23/07/2021
EXAMINER'S AMENDMENT ENTERED
23/07/2021
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
23/07/2021
EXAMINERS AMENDMENT E-MAILED
23/07/2021
EXAMINERS AMENDMENT -WRITTEN
23/07/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
13/07/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/07/2021
ASSIGNED TO LIE
09/07/2021
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/05/2021
CHANGE OF OWNER RECEIVED FROM IB
10/05/2021
NEW REPRESENTATIVE AT IB RECEIVED
09/04/2021
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/04/2021
CORRECTION TRANSACTION RECEIVED FROM IB
03/04/2021
NEW REPRESENTATIVE AT IB RECEIVED
05/03/2021
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
26/01/2021
LETTER OF SUSPENSION E-MAILED
26/01/2021
SUSPENSION LETTER WRITTEN
26/01/2021
TEAS REQUEST FOR RECONSIDERATION RECEIVED
19/01/2021
EX PARTE APPEAL-INSTITUTED
19/01/2021
JURISDICTION RESTORED TO EXAMINING ATTORNEY
19/01/2021
EXPARTE APPEAL RECEIVED AT TTAB
19/01/2021
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/10/2020
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/10/2020
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/10/2020
NOTIFICATION OF FINAL REFUSAL EMAILED
20/07/2020
FINAL REFUSAL E-MAILED
20/07/2020
FINAL REFUSAL WRITTEN
20/07/2020
TEAS/EMAIL CORRESPONDENCE ENTERED
14/07/2020
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/07/2020
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/07/2020
REFUSAL PROCESSED BY IB
15/05/2020
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/04/2020
REFUSAL PROCESSED BY MPU
28/04/2020
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/04/2020
NON-FINAL ACTION WRITTEN
10/04/2020
ASSIGNED TO EXAMINER
01/04/2020
APPLICATION FILING RECEIPT MAILED
21/03/2020
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/03/2020
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/03/2020
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.